Pay in 4 interest-free payments of $5.95 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
The SYNCHRONISE-CVOT trial will evaluate the cardiovascular safety of survodutide in participants with overweight or obesity and established CVD, chronic kidney disease or cardiovascular risk factors (clinical trial number NCT06077864
SJ: Conceptualization, Methodology, Resources, Validation, Writing original draft, Writing review & editing, Supervision
Using degraded medication can alter both efficacy and side effect profile
13 Future directions Future advances in GSH-responsive nanomedicine should focus on clinically relevant development rather than proof of concept designs
A care team will also determine eligibility based on safety
The post-treatment follow-up was performed after 12 and 24 weeks of treatment, plus a few days if necessary, so that patients were again evaluated on day 36 of the menstrual cycle (the first occurring after the 12 or 24 weeks of treatment)
